Humana Inc. (NYSE:HUM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Humana Inc. (NYSE:HUM) by 1.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 856,954 shares of the insurance provider’s stock after acquiring an additional 9,100 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Humana were worth $271,432,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Atria Investments Inc grew its position in shares of Humana by 14.5% during the first quarter. Atria Investments Inc now owns 5,329 shares of the insurance provider’s stock worth $1,848,000 after buying an additional 673 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Humana by 249.0% during the first quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock worth $7,262,000 after buying an additional 14,944 shares during the last quarter. Cetera Advisors LLC increased its holdings in shares of Humana by 472.1% in the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock valued at $3,501,000 after purchasing an additional 8,333 shares during the period. Kathmere Capital Management LLC purchased a new position in Humana during the 2nd quarter worth $170,000. Finally, Transcend Capital Advisors LLC acquired a new position in shares of Humana during the second quarter worth about $433,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 0.0 %

NYSE HUM opened at $296.78 on Friday. The company has a market capitalization of $35.74 billion, a price-to-earnings ratio of 26.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $504.79. The company’s fifty day moving average price is $275.33 and its two-hundred day moving average price is $329.47.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. As a group, research analysts predict that Humana Inc. will post 15.86 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio is presently 31.36%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on HUM shares. Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Barclays upped their price target on Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Truist Financial lowered their target price on Humana from $400.00 to $260.00 and set a “hold” rating on the stock in a report on Friday, October 11th. Oppenheimer dropped their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a report on Thursday, October 3rd. Finally, Jefferies Financial Group cut shares of Humana from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.